Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic constriction injury-induced neuropathic pain: Possible involvement of the opioid system

Yogesvari Sambasevam, Ahmad Akira Omar Farouk, Tengku Azam Shah Tengku Mohamad, Mohd Roslan Sulaiman, B. Hemabarathy Bharatham, Enoch Kumar Perimal

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Neuropathic pain arises from the injury of nervous system. The condition is extremely difficult to be treated due to the ineffectiveness and presence of various adverse effects of the currently available drugs. In the present study, we investigated the antiallodynic and antihyperlagesic properties of cardamonin, a naturally occurring chalcone in chronic constriction injury (CCI)-induced neuropathic pain mice model. Our findings showed that single and repeated dose of intra-peritoneal administration of cardamonin (3, 10, 30 mg/kg) significantly inhibited (P<0.001) the chronic constriction injury-induced neuropathic pain using the Hargreaves plantar test, Randall-Selitto analgesiometer test, dynamic plantar anesthesiometer test and the cold plate test in comparison with the positive control drug used (amitriptyline hydrochloride, 20 mg/kg, i.p.). Pre-treatment with naloxone hydrochloride (1 mg/kg, i.p.) and naloxone methiodide (1 mg/kg, s.c) significantly reversed the antiallodynic and antihyperalgesic effects of cardamonin in dynamic plantar anesthesiometer test and Hargreaves plantar test, respectively. In conclusion, the current findings demonstrated novel antiallodynic and antihyperalgesic effects of cardamonin through the activation of the opioidergic system both peripherally and centrally and may prove to be a potent lead compound for the development of neuropathic pain drugs in the future.

Original languageEnglish
Pages (from-to)32-38
Number of pages7
JournalEuropean Journal of Pharmacology
Volume796
DOIs
Publication statusPublished - 5 Feb 2017

Fingerprint

Hyperalgesia
Neuralgia
Constriction
Opioid Analgesics
Wounds and Injuries
Nervous System Trauma
Chalcone
Amitriptyline
Drug and Narcotic Control
Naloxone
Pharmaceutical Preparations
cardamonin
Therapeutics

Keywords

  • Allodynia
  • Cardamonin
  • CCI
  • Hyperalgesia
  • Neuropathic pain

ASJC Scopus subject areas

  • Pharmacology

Cite this

Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic constriction injury-induced neuropathic pain : Possible involvement of the opioid system. / Sambasevam, Yogesvari; Omar Farouk, Ahmad Akira; Tengku Mohamad, Tengku Azam Shah; Sulaiman, Mohd Roslan; Bharatham, B. Hemabarathy; Perimal, Enoch Kumar.

In: European Journal of Pharmacology, Vol. 796, 05.02.2017, p. 32-38.

Research output: Contribution to journalArticle

Sambasevam, Yogesvari ; Omar Farouk, Ahmad Akira ; Tengku Mohamad, Tengku Azam Shah ; Sulaiman, Mohd Roslan ; Bharatham, B. Hemabarathy ; Perimal, Enoch Kumar. / Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic constriction injury-induced neuropathic pain : Possible involvement of the opioid system. In: European Journal of Pharmacology. 2017 ; Vol. 796. pp. 32-38.
@article{a15e740f89a4406abee6058b19aae71c,
title = "Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic constriction injury-induced neuropathic pain: Possible involvement of the opioid system",
abstract = "Neuropathic pain arises from the injury of nervous system. The condition is extremely difficult to be treated due to the ineffectiveness and presence of various adverse effects of the currently available drugs. In the present study, we investigated the antiallodynic and antihyperlagesic properties of cardamonin, a naturally occurring chalcone in chronic constriction injury (CCI)-induced neuropathic pain mice model. Our findings showed that single and repeated dose of intra-peritoneal administration of cardamonin (3, 10, 30 mg/kg) significantly inhibited (P<0.001) the chronic constriction injury-induced neuropathic pain using the Hargreaves plantar test, Randall-Selitto analgesiometer test, dynamic plantar anesthesiometer test and the cold plate test in comparison with the positive control drug used (amitriptyline hydrochloride, 20 mg/kg, i.p.). Pre-treatment with naloxone hydrochloride (1 mg/kg, i.p.) and naloxone methiodide (1 mg/kg, s.c) significantly reversed the antiallodynic and antihyperalgesic effects of cardamonin in dynamic plantar anesthesiometer test and Hargreaves plantar test, respectively. In conclusion, the current findings demonstrated novel antiallodynic and antihyperalgesic effects of cardamonin through the activation of the opioidergic system both peripherally and centrally and may prove to be a potent lead compound for the development of neuropathic pain drugs in the future.",
keywords = "Allodynia, Cardamonin, CCI, Hyperalgesia, Neuropathic pain",
author = "Yogesvari Sambasevam and {Omar Farouk}, {Ahmad Akira} and {Tengku Mohamad}, {Tengku Azam Shah} and Sulaiman, {Mohd Roslan} and Bharatham, {B. Hemabarathy} and Perimal, {Enoch Kumar}",
year = "2017",
month = "2",
day = "5",
doi = "10.1016/j.ejphar.2016.12.020",
language = "English",
volume = "796",
pages = "32--38",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Cardamonin attenuates hyperalgesia and allodynia in a mouse model of chronic constriction injury-induced neuropathic pain

T2 - Possible involvement of the opioid system

AU - Sambasevam, Yogesvari

AU - Omar Farouk, Ahmad Akira

AU - Tengku Mohamad, Tengku Azam Shah

AU - Sulaiman, Mohd Roslan

AU - Bharatham, B. Hemabarathy

AU - Perimal, Enoch Kumar

PY - 2017/2/5

Y1 - 2017/2/5

N2 - Neuropathic pain arises from the injury of nervous system. The condition is extremely difficult to be treated due to the ineffectiveness and presence of various adverse effects of the currently available drugs. In the present study, we investigated the antiallodynic and antihyperlagesic properties of cardamonin, a naturally occurring chalcone in chronic constriction injury (CCI)-induced neuropathic pain mice model. Our findings showed that single and repeated dose of intra-peritoneal administration of cardamonin (3, 10, 30 mg/kg) significantly inhibited (P<0.001) the chronic constriction injury-induced neuropathic pain using the Hargreaves plantar test, Randall-Selitto analgesiometer test, dynamic plantar anesthesiometer test and the cold plate test in comparison with the positive control drug used (amitriptyline hydrochloride, 20 mg/kg, i.p.). Pre-treatment with naloxone hydrochloride (1 mg/kg, i.p.) and naloxone methiodide (1 mg/kg, s.c) significantly reversed the antiallodynic and antihyperalgesic effects of cardamonin in dynamic plantar anesthesiometer test and Hargreaves plantar test, respectively. In conclusion, the current findings demonstrated novel antiallodynic and antihyperalgesic effects of cardamonin through the activation of the opioidergic system both peripherally and centrally and may prove to be a potent lead compound for the development of neuropathic pain drugs in the future.

AB - Neuropathic pain arises from the injury of nervous system. The condition is extremely difficult to be treated due to the ineffectiveness and presence of various adverse effects of the currently available drugs. In the present study, we investigated the antiallodynic and antihyperlagesic properties of cardamonin, a naturally occurring chalcone in chronic constriction injury (CCI)-induced neuropathic pain mice model. Our findings showed that single and repeated dose of intra-peritoneal administration of cardamonin (3, 10, 30 mg/kg) significantly inhibited (P<0.001) the chronic constriction injury-induced neuropathic pain using the Hargreaves plantar test, Randall-Selitto analgesiometer test, dynamic plantar anesthesiometer test and the cold plate test in comparison with the positive control drug used (amitriptyline hydrochloride, 20 mg/kg, i.p.). Pre-treatment with naloxone hydrochloride (1 mg/kg, i.p.) and naloxone methiodide (1 mg/kg, s.c) significantly reversed the antiallodynic and antihyperalgesic effects of cardamonin in dynamic plantar anesthesiometer test and Hargreaves plantar test, respectively. In conclusion, the current findings demonstrated novel antiallodynic and antihyperalgesic effects of cardamonin through the activation of the opioidergic system both peripherally and centrally and may prove to be a potent lead compound for the development of neuropathic pain drugs in the future.

KW - Allodynia

KW - Cardamonin

KW - CCI

KW - Hyperalgesia

KW - Neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=85006300324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006300324&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2016.12.020

DO - 10.1016/j.ejphar.2016.12.020

M3 - Article

C2 - 27988285

AN - SCOPUS:85006300324

VL - 796

SP - 32

EP - 38

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -